Trellis Bioscience

US-based Trellis Bioscience develops therapeutic antibody treatments for infectious diseases and cancer.

: 75
: Company
: 1998
: San Francisco, CA, USUnited States

Library

trellisbio.comCrawled Sep 28, 2026

Homepage

1 page

Homepage/
Trellis Bioscience is developing native human antibodies to disrupt bacterial biofilms and address difficult-to-treat infections.

Coverage

5 items

Trellis Bioscience Raises $9M in Series C Fundingfinsmes.com/2026/07/trellis-bioscience-raises-9m-in-series-c-funding.html
Trellis Bioscience secures **$9 million in Series C funding** to advance its pipeline of **native human monoclonal antibodies (mAbs)** targeting **intractable infectious diseases**. The Redwood City, CA-based biotech company focuses on clinical-stage development to address unmet medical needs in infectious disease treatment.
Jul 2026FinSMEsNews article
Trellis Bioscience Raises $9 Million to Advance Phase 2 Trial of Biofilm-Targeting Therapy for Prosthetic Joint Infectionscitybiz.co/article/875817/trellis-bioscience-raises-9-million-to-advance-phase-2-trial-of-biofilm-targeting-therapy-for-prosthetic-joint-infections/
Trellis Bioscience secures $9 million in Series C funding to finalize its Phase 2 clinical trial of a biofilm-targeting therapy designed to treat prosthetic joint infections. The therapy aims to address infections caused by bacterial biofilms, a common complication in joint replacement surgeries. The funding will accelerate development of this potential treatment for patients with chronic infections.
Jul 2026citybizNews article
TRELLIS BIOSCIENCE RAISES $9 MILLION TO ADVANCE CLINICAL DEVELOPMENT OF CALPURBATUG (TRL1068)aol.com/articles/trellis-bioscience-raises-9-million-213300000.html
Trellis Bioscience secures $9 million in funding to advance **Calpurbatug (TRL1068)**, an experimental therapy targeting **prosthetic joint infections (PJI)**. The capital will accelerate clinical development of this novel treatment, positioning it as a potential solution for patients with infected joint replacements. The therapy remains under evaluation for safety and efficacy in late-stage trials.
Jul 2026AOL.comNews article
Trellis Bioscience's TRL1068 Study Published in AAC: A Breakthrough in AMRfinance.yahoo.com/news/trellis-biosciences-trl1068-study-published-003500396.html
Trellis Bioscience publishes peer-reviewed results of its TRL1068 study in *Antimicrobial Agents and Chemotherapy*, marking a milestone in antimicrobial resistance (AMR) research. The clinical study evaluates a potential treatment targeting drug-resistant infections. The publication follows rigorous peer review in a top infectious disease journal, validating the compound’s development progress.
Jul 2024Yahoo FinanceNews article